TAR RNA

By Targets:	DNA/RNA Synthesis (4) Antibiotic (3) Bacterial (3) HIV (1) Isotope-Labeled Compounds (1) MicroRNA (3)
By Research Areas:	Cancer (4) Infection (3) Inflammation/Immunology (1)

Targets Recommended: DNA/RNA Synthesis Small Interfering RNA (siRNA)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147918

Anticancer agent 73	DNA/RNA Synthesis	Cancer
Anticancer agent 73 (compound CIB-3b) is a anticancer agent, potently targeting TAR RNA-binding protein 2 (TRBP) and disrupts its interaction with Dicer. Anticancer agent 73 can rebalance the expression profile of oncogenic or tumor-suppressive miRNAs. Anticancer agent 73 suppresses the proliferation and metastasis of HCC in vitro and in vivo .

HY-B0268A

Enoxacin hydrate 1 Publications Verification Enoxacin sesquihydrate; AT-2266 hydrate; CI-919 hydrate	Bacterial DNA/RNA Synthesis MicroRNA Antibiotic	Infection Cancer
Enoxacin hydrate (Enoxacin sesquihydrate), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 µg/ml) and topoisomerase IV (IC₅₀=26.5 µg/ml). Enoxacin hydrate is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin hydrate has potent activities against gram-positive and -negative bacteria. Enoxacin hydrate is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

HY-B0268S1

Enoxacin-d8 hydrochloride	Isotope-Labeled Compounds Bacterial DNA/RNA Synthesis MicroRNA Antibiotic	Infection Cancer
Enoxacin-d₈ (hydrochloride) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing[1][2][3][4].

HY-146382

WRNA10

HIV Inflammation/Immunology

WRNA10 is a potent HIV-1 TAR RNA binder with an IC₅₀ of 10 µM and an CC₅₀ of 40 µM .

WRNA10	HIV	Inflammation/Immunology
WRNA10 is a potent HIV-1 TAR RNA binder with an IC₅₀ of 10 µM and an CC₅₀ of 40 µM .

HY-B0268

Enoxacin AT 2266; CI 919	Bacterial DNA/RNA Synthesis MicroRNA Antibiotic	Infection Cancer
Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC₅₀=126 µg/ml) and topoisomerase IV (IC₅₀=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .

Species:	Human (2)
Tag:	His (1) Strep (1) Flag (2)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P702000

	LRRFIP1 Protein, Human (FLAG) LRRFIP1; Leucine-rich repeat flightless-interacting protein 1; LRR FLII-interacting protein 1; GC-binding factor 2; TAR RNA-interacting protein	Human	E. coli
	LRRFIP1 is a transcriptional repressor that preferentially binds to GC-rich sequences (5'-AGCCCCCGGCG-3') and may regulate the expression of TNF, EGFR, and PDGFA. It inhibits PDGFA, which controls smooth muscle cell proliferation after arterial injury. LRRFIP1 Protein, Human (FLAG) is the recombinant human-derived LRRFIP1 protein, expressed by E. coli , with C-Flag labeled tag. The total length of LRRFIP1 Protein, Human (FLAG) is 808 a.a., .

HY-P702001

	LRRFIP1 Protein, Human (His, Strep) LRRFIP1; Leucine-rich repeat flightless-interacting protein 1; LRR FLII-interacting protein 1; GC-binding factor 2; TAR RNA-interacting protein	Human	E. coli
	LRRFIP1 is a transcriptional repressor that preferentially binds to GC-rich sequences (5'-AGCCCCCGGCG-3') and may regulate the expression of TNF, EGFR, and PDGFA. It inhibits PDGFA, which controls smooth muscle cell proliferation after arterial injury. LRRFIP1 Protein, Human (His, Strep) is the recombinant human-derived LRRFIP1 protein, expressed by E. coli , with N-Strep, N-6*His labeled tag. The total length of LRRFIP1 Protein, Human (His, Strep) is 808 a.a., .


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B0268S1

Enoxacin-d8 hydrochloride
Enoxacin-d₈ (hydrochloride) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing[1][2][3][4].

Enoxacin-d8 hydrochloride

Enoxacin-d₈ (hydrochloride) is deuterium labeled Enoxacin. Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing[1][2][3][4].

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Recombinant Proteins

Isotope-Labeled Compounds

Name
Email *

	Sorry, but the email address you supplied was invalid.